Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 14Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Hepatocellular 4Triple Negative Breast Neoplasms 3Sarcoma, Ewing 3Ovarian Neoplasms 3Melanoma 3Kidney Neoplasms 3Pancreatic Neoplasms 2Osteosarcoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2HIV Infections 2Endometrial Neoplasms 2Carcinoma, Medullary 2Breast Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Hormone Refractory Prostate Cancer × cabozantinib × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡